Mylin Holdings Group

Mylin Holdings Group, primarily operating through its subsidiary Mylin (Shanghai) Biotechnology, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in autoimmune diseases, inflammatory conditions, and oncology by targeting key biological pathways such as RORγt and TYK2. Its lead program, MLN-101, is a potent and selective RORγt antagonist currently in Phase 2 clinical development for the treatment of plaque psoriasis and other Th17-mediated inflammatory diseases. Mylin leverages a proprietary drug discovery platform and structure-based drug design to generate a robust pipeline of high-quality candidates. Headquartered in Shanghai, the company is backed by prominent life science investors and aims to deliver transformative medicines to patients globally.